688266 泽璟制药
已收盘 03-13 15:00:01
资讯
新帖
简况
3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股
证券之星 · 03-10
3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股
每周股票复盘：泽璟制药（688266）2025年净亏1.607亿
证券之星 · 03-01
每周股票复盘：泽璟制药（688266）2025年净亏1.607亿
泽璟制药发布2025年度业绩快报，亏损1.607亿元
证券之星 · 02-27
泽璟制药发布2025年度业绩快报，亏损1.607亿元
2月24日泽璟制药跌9.28%，汇添富创新医药混合A基金重仓该股
证券之星 · 02-24
2月24日泽璟制药跌9.28%，汇添富创新医药混合A基金重仓该股
【机构调研记录】平安基金调研泽璟制药、方盛制药
证券之星 · 02-16
【机构调研记录】平安基金调研泽璟制药、方盛制药
泽璟制药：股东ZELINSHENG（盛泽林）及宁波泽奥拟减持公司股份
证券之星 · 02-14
泽璟制药：股东ZELINSHENG（盛泽林）及宁波泽奥拟减持公司股份
泽璟制药公布国际专利申请：“卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用”
证券之星 · 01-31
泽璟制药公布国际专利申请：“卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用”
每周股票复盘：泽璟制药（688266）ZG005获临床试验批准
证券之星 · 01-25
每周股票复盘：泽璟制药（688266）ZG005获临床试验批准
泽璟制药（688266）披露实际控制人续签一致行动协议公告，1月23日股价上涨2.69%
证券之星 · 01-23
泽璟制药（688266）披露实际控制人续签一致行动协议公告，1月23日股价上涨2.69%
泽璟制药：注射用ZG005与含铂化疗联用获得药物临床试验批准通知书
证券之星 · 01-22
泽璟制药：注射用ZG005与含铂化疗联用获得药物临床试验批准通知书
每周股票复盘：泽璟制药（688266）双抗联合疗法获临床批准
证券之星 · 01-18
每周股票复盘：泽璟制药（688266）双抗联合疗法获临床批准
泽璟制药：注射用ZGGS18与注射用ZG005及化疗联用获得药物临床试验批准通知书
证券之星 · 01-15
泽璟制药：注射用ZGGS18与注射用ZG005及化疗联用获得药物临床试验批准通知书
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β获批上市
证券之星 · 01-11
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β获批上市
泽璟制药(688266.SH)：注射用人促甲状腺素β获批上市
智通财经 · 01-08
泽璟制药(688266.SH)：注射用人促甲状腺素β获批上市
每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款
证券之星 · 01-02
每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款
泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款
美股速递 · 2025-12-31
泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款
泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化
美股速递 · 2025-12-31
泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化
泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议
智通财经 · 2025-12-31
泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议
每周股票复盘：泽璟制药（688266）递交H股上市申请
证券之星 · 2025-12-28
每周股票复盘：泽璟制药（688266）递交H股上市申请
泽璟制药递表港交所 拥有三款已上市药物
智通财经 · 2025-12-22
泽璟制药递表港交所 拥有三款已上市药物
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药","latestPrice":78.95,"timestamp":1773385201000,"preClose":80.8,"halted":0,"volume":2026364,"delay":0,"changeRate":-0.0229,"floatShares":265000000,"shares":265000000,"eps":-0.5038,"marketStatus":"已收盘","change":-1.85,"latestTime":"03-13 15:00:01","open":80.8,"high":80.8,"low":78.58,"amount":161000000,"amplitude":0.0275,"askPrice":78.95,"askSize":30,"bidPrice":78.94,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.5038,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":5,"adr":0,"adjPreClose":80.8,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773365400000,1773372600000],[1773378000000,1773385200000]],"highLimit":88.88,"lowLimit":72.72,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":18.19,"roa":"--","roe":"--","epsLYR":-0.52,"committee":0.504644,"marketValue":20899000000,"turnoverRate":0.0077,"status":1,"afterMarket":{"amount":0,"volume":0,"close":78.95,"buyVolume":0,"sellVolume":0,"time":1773387237558,"indexStatus":"已收盘 03-13 15:30:00","preClose":80.8},"floatMarketCap":20899000000},"requestUrl":"/m/hq/s/688266/wiki","defaultTab":"wiki","newsList":[{"id":"2618980695","title":"3月10日泽璟制药涨7.24%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980695","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980695?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:21","pubTimestamp":1773130879,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日泽璟制药涨7.24%，收盘报85.8元，换手率1.52%，成交量4.01万手，成交额3.41亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共84家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为72.69亿元，最新净值1.616，较上一交易日下跌1.67%，近一年上涨22.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000024253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","BK1574","BK1161","159938","09939","688266"],"gpt_icon":0},{"id":"2616843553","title":"每周股票复盘：泽璟制药（688266）2025年净亏1.607亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843553","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843553?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:56","pubTimestamp":1772301371,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，泽璟制药报收于82.12元，较上周的94.42元下跌13.03%。本周，泽璟制药2月24日盘中最高价报94.94元。泽璟制药当前最新总市值217.38亿元，在化学制药板块市值排名20/150，在两市A股市值排名1017/5189。本周关注点来自业绩披露要点：泽璟制药2025年归属净利润亏损1.607亿元，同比扩大16.59%。公司公告汇总苏州泽璟生物制药股份有限公司发布2025年度业绩快报，营业总收入为81,273.36万元，同比增长52.50%。总资产为297,143.46万元，归属于母公司的所有者权益为108,269.72万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2614835080","title":"泽璟制药发布2025年度业绩快报，亏损1.607亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835080?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:24","pubTimestamp":1772184268,"startTime":"0","endTime":"0","summary":"证券之星消息，泽璟制药近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损1.607亿元，同比减少16.59%。2025年末，公司总资产297,143.46万元，归属于母公司的所有者权益108,269.72万元，归属于母公司所有者的每股净资产4.09元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700029044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2613795592","title":"2月24日泽璟制药跌9.28%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613795592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613795592?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:26","pubTimestamp":1771921591,"startTime":"0","endTime":"0","summary":"证券之星消息，2月24日泽璟制药跌9.28%创60日新低，收盘报85.66元，换手率2.04%，成交量5.41万手，成交额4.72亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共84家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为72.69亿元，最新净值1.7449，较上一交易日下跌0.89%，近一年上涨39.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400030092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688266","09939","BK1161","159938","BK1515","BK0239"],"gpt_icon":0},{"id":"2611171901","title":"【机构调研记录】平安基金调研泽璟制药、方盛制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2611171901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611171901?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:01","pubTimestamp":1771200068,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及2月13日披露的机构调研信息，平安基金近期对2家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：泽璟制药与艾伯维就ZG006达成战略合作，艾伯维获大中华区以外开发与商业化权利，泽璟获1亿美元首付款。重组人凝血酶由远大生命科学推广，销量增长明显，已纳入两项权威指南。研发费用率预计将平稳上升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021600000189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","688266","BK0239"],"gpt_icon":0},{"id":"2611916433","title":"泽璟制药：股东ZELINSHENG（盛泽林）及宁波泽奥拟减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2611916433","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611916433?lang=zh_cn&edition=full","pubTime":"2026-02-14 00:01","pubTimestamp":1770998500,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称，股东ZELIN SHENG（盛泽林）拟减持不超过273,907股，占公司总股本的0.1035%；股东宁波泽奥拟减持不超过2,475,090股，占公司总股本的0.9350%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021400000005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2607050022","title":"泽璟制药公布国际专利申请：“卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050022","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050022?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:45","pubTimestamp":1769813146,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示泽璟制药（688266）公布了一项国际专利申请，专利名为“卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用”，专利申请号为PCT/CN2025/110184，国际公布日为2026年1月29日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来泽璟制药已公布的国际专利申请1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.97亿元，同比增8.47%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100005194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2606232332","title":"每周股票复盘：泽璟制药（688266）ZG005获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232332","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232332?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:22","pubTimestamp":1769278932,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，泽璟制药报收于87.8元，较上周的94.09元下跌6.69%。本周，泽璟制药1月19日盘中最高价报94.22元。该临床试验获批对公司近期业绩无重大影响，药品研发仍存在不确定性风险。泽璟制药关于实际控制人续签一致行动协议的公告苏州泽璟生物制药股份有限公司实际控制人ZELIN SHENG（盛泽林）先生和陆惠萍女士于2026年1月23日续签《一致行动协议》，协议有效期为12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2605406378","title":"泽璟制药（688266）披露实际控制人续签一致行动协议公告，1月23日股价上涨2.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605406378","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605406378?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:37","pubTimestamp":1769179039,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，泽璟制药报收于87.8元，较前一交易日上涨2.69%，最新总市值为232.41亿元。近日，苏州泽璟生物制药股份有限公司发布《关于实际控制人续签一致行动协议的公告》。公告显示，公司实际控制人ZELIN SHENG（盛泽林）先生和陆惠萍女士于2026年1月23日续签《一致行动协议》，协议有效期为12个月。截至公告日，ZELIN SHENG（盛泽林）持有公司18.85%股份，陆惠萍持有4.77%，合计持股23.63%。本次续签不影响公司实际控制权，有利于控制权稳定及经营连续性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2605464992","title":"泽璟制药：注射用ZG005与含铂化疗联用获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605464992","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605464992?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:44","pubTimestamp":1769075074,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG005与含铂化疗联合用于晚期鼻咽癌和食管鳞癌的临床试验获得批准。该药物为创新型肿瘤免疫治疗生物制品，有望用于治疗多种实体瘤。由于药品研发周期长、审批环节多，存在无法获批上市销售的风险，对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200029446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2604925734","title":"每周股票复盘：泽璟制药（688266）双抗联合疗法获临床批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925734","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925734?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:29","pubTimestamp":1768681746,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，泽璟制药报收于94.09元，较上周的98.8元下跌4.77%。本周关注点公司公告汇总：注射用ZGGS18联合ZG005及化疗获临床试验批准。公司公告汇总泽璟制药关于自愿披露注射用ZGGS18与注射用ZG005及化疗联用获得药物临床试验批准通知书的公告苏州泽璟生物制药股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用ZGGS18联合注射用ZG005及化疗在晚期实体瘤患者中开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2603603162","title":"泽璟制药：注射用ZGGS18与注射用ZG005及化疗联用获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603162","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603162?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:41","pubTimestamp":1768470069,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZGGS18与注射用ZG005及化疗联合用于晚期实体瘤的临床试验获得批准。本次临床试验获批事项对公司近期业绩不会产生重大影响。由于药品研发周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2602535696","title":"每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535696","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535696?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:43","pubTimestamp":1768070587,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，泽璟制药报收于98.8元，较上周的92.7元上涨6.58%。本周，泽璟制药1月8日盘中最高价报100.66元。本周关注点公司公告汇总：泽璟制药自主研发的注射用人促甲状腺素β获批上市，为我国首个用于分化型甲状腺癌术后精准评估的创新产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2601524823","title":"泽璟制药(688266.SH)：注射用人促甲状腺素β获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601524823","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601524823?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:26","pubTimestamp":1767864360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，2026年1月8日，公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的注射用人促甲状腺素β(曾用名：注射用重组人促甲状腺激素，商标：泽速宁®)的新药上市申请获得批准，本次获批的适应症为：“用于分化型甲状腺癌患者在甲状腺全切或近全切除术后随访中的协同诊断，以进行血清甲状腺球蛋白(Tg)检测，伴或不伴放射性碘(131I)全身显像(WBS)检查”。注射用人促甲状腺素β是我国首个获批用于分化型甲状腺癌术后精准评估的创新产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2600035009","title":"每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035009?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:24","pubTimestamp":1767291851,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，泽璟制药报收于99.53元，较上周的101.33元下跌1.78%。本周关注点公司公告汇总：泽璟制药与艾伯维就ZG006达成全球合作，获1亿美元首付款。公司公告汇总：艾伯维可支付泽璟制药最高达10.75亿美元的里程碑款项。泽璟将获得1亿美元首付款，以及最高6000万美元的近期里程碑及许可选择相关付款；若艾伯维行使许可选择权，泽璟还可获得最高10.75亿美元里程碑付款，并享有海外净销售额的阶梯式特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"1165741365","title":"泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1165741365","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165741365?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:31","pubTimestamp":1767173475,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，若合作方艾伯维公司行使许可选择权，公司将获得1亿美元的首付款，并有资格获得最高达11亿美元的里程碑付款。此次合作涉及特定创新药物的授权许可，彰显了泽璟制药研发实力的国际认可。协议具体条款将根据研发进展分阶段触发付款条件，为泽璟制药带来长期现金流支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550494.USD","LU1162221912.USD","LU0114720955.EUR","LU0689626769.HKD","BK4550","SG9999015986.USD","LU1267930490.SGD","IE0009355771.USD","LU2129689605.HKD","LU0211328371.USD","LU1093756168.USD","LU0256863902.USD","LU0820561909.HKD","LU0432979614.USD","LU1074936037.SGD","BK4566","LU2237443978.SGD","SG9999003800.SGD","LU0545039389.USD","BK4585","LU1496350502.SGD","SG9999015945.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU1244550221.USD","LU1037948541.HKD","LU1267930573.SGD","LU0861579265.USD","IE0002270589.USD","LU2237443465.HKD","LU1934455277.USD","LU0985320562.USD","LU0320765646.SGD","LU0128525929.USD","688266","LU1929549753.HKD","LU2133065610.SGD","LU0795875086.SGD","ABBV","LU2347655156.SGD","LU0158827948.USD","LU1003077747.HKD","LU1989772923.USD","LU0912757837.SGD","LU2237443549.SGD","LU1430594728.SGD","LU0965509283.SGD","LU2237443895.HKD","LU0965509101.SGD","LU0211327993.USD","LU2023251221.USD","LU0882574055.USD","LU0965508806.USD","LU0170899867.USD","LU0943347566.SGD","LU2237443382.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU1551013342.USD","BK4559","LU0738911758.USD","LU1057294990.SGD","BK4581","LU0058720904.USD","LU0795875169.SGD","LU1291159041.SGD","LU1989771016.USD","LU2089284900.SGD","SG9999011175.SGD","LU1093756325.SGD","IE0004445239.USD","LU0965509010.AUD","LU0098860793.USD","LU2089984988.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0553294199.USD","LU0689472784.USD","LU0456855351.SGD","IE00B2B36J28.USD","IE00BVYPNW00.USD","LU0256863811.USD","LU1037948897.HKD","LU1989772840.SGD","IE00BLSP4239.USD","LU0198837287.USD","LU2089283258.USD","BK4534","IE00BBT3K403.USD","LU1496350171.SGD","LU1983299246.USD","LU2129689514.USD","LU2468319806.SGD","IE00BVYPNV92.GBP","LU0661504455.SGD","SG9999015952.SGD","IE00B42XCP33.USD","LU1718418525.SGD","LU0417517546.SGD","IE00BDGV0183.EUR","LU1732799900.SGD","LU1934455194.USD","BK4588","LU0949170772.SGD","LU0820561818.USD","LU0310799852.SGD","BK4139","IE00B3PB1722.GBP","LU0203347892.USD","LU0203345920.USD","LU1839511570.USD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","BK0239","LU1023059063.AUD","LU2237443622.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","SG9999015978.USD","BK4533","LU0234570918.USD","LU2087621335.USD","LU2129689431.USD","IE00BN8TJ469.HKD","LU1934455863.HKD","IE0002141913.USD","LU1244550577.SGD","LU1551013425.SGD","LU2112291526.USD","IE00BGHQF631.EUR","LU0124676726.USD","LU0234572021.USD","LU0029864427.USD","LU1732800096.USD","IE00BLSP4452.SGD","LU0708994859.HKD","LU1585245621.USD","LU0310800379.SGD"],"gpt_icon":0},{"id":"1177773699","title":"泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1177773699","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177773699?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:31","pubTimestamp":1767173473,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，已与艾伯维公司签署一项战略合作协议，双方将就阿尔维塔米格的开发及商业化展开深度合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4559","IE00B42XCP33.USD","LU1267930573.SGD","LU1037948541.HKD","IE00BVYPNV92.GBP","LU1551013425.SGD","LU2237443978.SGD","SG9999015952.SGD","IE00B2B36J28.USD","LU1989772923.USD","LU0861579265.USD","IE00BFTCPJ56.SGD","LU0234570918.USD","IE0004445239.USD","LU0310799852.SGD","688266","LU1585245621.USD","ABBV","LU0965509010.AUD","LU0943347566.SGD","LU0211328371.USD","LU1934455863.HKD","BK4581","IE0002141913.USD","LU0203345920.USD","LU1093756168.USD","SG9999015945.SGD","LU0965509101.SGD","LU0289739699.SGD","LU1162221912.USD","LU2129689605.HKD","IE00BN8TJ469.HKD","LU0912757837.SGD","LU0689626769.HKD","LU1989772840.SGD","LU0256863811.USD","LU2237443895.HKD","SG9999011175.SGD","LU0965508806.USD","LU2468319806.SGD","LU1244550221.USD","IE00B4R5TH58.HKD","LU0882574055.USD","LU1093756325.SGD","LU0795875086.SGD","LU0708994859.HKD","SG9999001440.SGD","LU0158827948.USD","LU0965509283.SGD","LU0553294199.USD","LU0949170772.SGD","LU0320765646.SGD","IE00BBT3K403.USD","LU0256863902.USD","LU0689472784.USD","LU0661504455.SGD","LU0820561818.USD","LU1037948897.HKD","LU2023251221.USD","BK4534","LU2237443465.HKD","LU1989771016.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU0310800379.SGD","LU0795875169.SGD","LU1496350171.SGD","LU0203347892.USD","LU1057294990.SGD","LU1244550494.USD","LU1929549753.HKD","LU0124676726.USD","LU1934455277.USD","LU2089984988.USD","LU2087621335.USD","IE00BGHQF631.EUR","LU0128525929.USD","LU2133065610.SGD","LU1061106388.HKD","LU1291159041.SGD","SG9999015986.USD","IE00BVYPNW00.USD","IE00B19Z3B42.SGD","LU2347655156.SGD","LU0098860793.USD","LU0234572021.USD","BK4588","BK4139","LU2237443549.SGD","LU0456855351.SGD","LU1267930490.SGD","BK4550","BK4585","LU1430594728.SGD","IE00BDGV0183.EUR","LU1732799900.SGD","LU1074936037.SGD","LU0985320562.USD","LU2129689431.USD","LU0029864427.USD","LU0417517546.SGD","LU2129689514.USD","SG9999003800.SGD","IE0009355771.USD","LU1839511570.USD","LU0198837287.USD","LU1551013342.USD","LU1934455194.USD","LU0211327993.USD","LU1983299246.USD","BK4566","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4533","IE00BJT1NW94.SGD","BK0239","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU0820561909.HKD","LU1718418525.SGD","LU1244550577.SGD","LU0170899867.USD","LU2112291526.USD","IE00B3PB1722.GBP","LU0114720955.EUR","LU0738911758.USD","LU1003077747.HKD","SG9999015978.USD","LU0432979614.USD","LU1496350502.SGD","LU0058720904.USD","LU0545039389.USD","IE00BLSP4239.USD","LU1732800096.USD","LU2089283258.USD","LU2237443382.USD","LU2237443622.USD","LU2089284900.SGD"],"gpt_icon":0},{"id":"2595724052","title":"泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595724052","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595724052?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:27","pubTimestamp":1767169654,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司与艾伯维集团控股公司就ZG006的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006在大中华区以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的开发与商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2594440432","title":"每周股票复盘：泽璟制药（688266）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2594440432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594440432?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:28","pubTimestamp":1766863692,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，泽璟制药报收于99.53元，较上周的101.33元下跌1.78%。本周，泽璟制药12月25日盘中最高价报103.4元。泽璟制药当前最新总市值263.46亿元，在化学制药板块市值排名17/151，在两市A股市值排名752/5178。本周关注点公司公告汇总：泽璟制药向香港联交所递交H股发行上市申请并刊发申请资料。该申请材料为按香港证监会及香港联交所要求编制的草拟版本，可能更新修订，不构成认购H股的要约或要约邀请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2593629106","title":"泽璟制药递表港交所 拥有三款已上市药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2593629106","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593629106?lang=zh_cn&edition=full","pubTime":"2025-12-22 13:32","pubTimestamp":1766381520,"startTime":"0","endTime":"0","summary":"据港交所12月19日披露，苏州泽璟生物制药股份有限公司(简称：泽璟制药)(688266.SH)向港交所主板提交上市申请，中金公司为其独家保荐人。公司简介招股书显示，泽璟制药为一家综合生物制药企 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251222/c673393834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688266","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773402969335,"stockEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":-0.1579},{"period":"3month","weight":-0.2615},{"period":"6month","weight":-0.2818},{"period":"1year","weight":-0.0871},{"period":"ytd","weight":-0.1284}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":0.0002},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.0668},{"period":"1year","weight":0.2246},{"period":"ytd","weight":0.0404}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8809人(较上一季度增加0.16%)","perCapita":"30049股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药,688266,泽璟制药股票,泽璟制药股票老虎,泽璟制药股票老虎国际,泽璟制药行情,泽璟制药股票行情,泽璟制药股价,泽璟制药股市,泽璟制药股票价格,泽璟制药股票交易,泽璟制药股票购买,泽璟制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}